Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Current ratio
Vertex Pharmaceuticals Incorporated's current ratio at the end of the quarter to 30 June 2026 was 3.2×, up 0.3× from fiscal 2025 (2.9×). Over the past ten years it has ranged from 2.3× (fiscal 2016) to 4.8× (fiscal 2022); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 4.7× and above the Healthcare sector median of 3.0×.
Current ratio, annual
Annual
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.9× | 7.76% |
| FY2024 | 2.7× | (32.48%) |
| FY2023 | 4.0× | (17.39%) |
| FY2022 | 4.8× | 8.14% |
| FY2021 | 4.5× | 3.03% |
| FY2020 | 4.3× | 19.90% |
| FY2019 | 3.6× | 5.32% |
| FY2018 | 3.4× | 4.54% |
| FY2017 | 3.3× | 41.99% |
| FY2016 | 2.3× | (16.87%) |
Quarterly
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 3.2× | 5.38% |
| Mar 2026 | 3.0× | 4.20% |
| Dec 2025 | 2.9× | 22.83% |
| Sep 2025 | 2.4× | (6.27%) |
| 42 more quarters | Free account |
Against its own ten years
Low 2.3×
High 4.8×
Ten-year median
3.4×
Current reading's percentile
36
Current ratio against peers
| Company | Current ratio |
|---|---|
| RVMD Revolution Medicines, Inc. compare | 11.4× |
| ARGX argenex SE compare | 5.1× |
| INSM Insmed, Inc. compare | 3.7× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 3.4× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 3.3× |
| VRTX Vertex Pharmaceuticals Incorporated | 3.2× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 3.1× |
| RPRX Royalty Pharma PLC compare | 2.8× |
| MRNA Moderna, Inc. compare | 2.3× |
| Biotechnology industry median | 4.7× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement